This website uses cookies to improve your experience. Learn more about cookies and how to manage them.

PR&P launch a themed issue celebrating Early Career Researchers

Back to Homepage

Published: 27 Mar 2019
Category: Journals, Early career pharmacologists
By Andrew Lawrence, Michael Jarvis

Pharmacology Research & Perspectives (PR&P) is a rapidly growing open access journal that is jointly published by the British Pharmacological Society, American Society for Pharmacology and Experimental Therapeutics (ASPET) and Wiley. PR&P publishes original research and topical reviews or commentaries covering all aspects of pharmacology research and drug discovery enabling sciences including preclinical research, target validation (or invalidation), translational medicine and clinical development.

PR&P receives cascaded submissions from a diverse set of supporter journals and the editorial board strongly encourages direct submission of original research and review papers communicating novel pharmacological hypotheses and insights as well as important replication data that advance or refute key pharmacology dogma. PR&P also encourages the direct submission of short communications that report novel pharmacological advances. PR&P highly values its diverse readership, authors, and editorial board and is dedicated to providing authors with the opportunity to publish quality research that may otherwise have gone unnoticed by utilising both Societies’ and Wiley’s well developed author and readership networks.

PR&P supporter journals

  • Basic & Clinical Pharmacology & Toxicology
  • British Journal of Pharmacology (British Pharmacological Society)
  • British Journal of Clinical Pharmacology (British Pharmacological Society)
  • Drug Metabolism and Disposition (ASPET)
  • Journal of Pharmacology
  • Journal of Pharmacology and Experimental Therapeutics (ASPET)
  • Molecular Pharmacology (ASPET)
  • Pharmacoepidemiology & Drug Safety
  • The Journal of Clinical Pharmacology

The PR&P editorial board is committed to providing authors with timely, relevant and instructive feedback on all submissions. For papers cascaded from supporting journals with prior peer review feedback, editorial decisions will be provided to authors within seven to 10 days. For original submissions or cascaded papers requiring peer review, time to first decision is usually within 21 days.

Open science and open access publishing have seen steady growth over the last decade. As an open access journal, papers published in PR&P are freely available to read, download and share globally. In this regard, PR&P is fully compliant with all public and private funding body requirements. PR&P’s open access publishing format is based on Article Publication Charge (APC) fees that are competitive compared to other similar open access journals. PR&P’s APCs for direct submissions are $2,500/£1,625/€1,900, if you receive a referral from one of ASPET or the Society’s feeder journals there is a 20% discount, bringing the cost down to $2,000/£1,300/€1,520. ASPET and British Pharmacological Society members also receive a 10% discount on APCs.

APC fees also help fund many important scholarly initiatives and mentoring activities of both societies including symposia sponsorships and program support aimed at career development for young scientists. In addition, for those with genuine hardship a limited fee waiver program exists.

Consistent with its mission to advance all aspects of pharmacological science, PR&P recently published two joint virtual issues that highlight state of the art pharmacological research in the areas of pain and diabetes. The articles contained in these joint virtual issues offer a diverse array of important scientific insights into cell surface receptors, biochemical signalling mechanisms, and experimental models that collectively contribute an increased understanding of disease pathology, current treatments, and emerging therapeutic interventions. Other virtual issues, such as ‘Celebrating 20 Years of Nitric Oxide Research’ and ‘Infectious Diseases’ have similarly been published have similarly been published with the Society's partner journals.

PR&P is also committed to supporting scientific development opportunities for early career researchers (ECRs), which include undergraduate, graduate or post-doctoral scientists. In this regard, PR&P is proud to announce its inaugural meeting sponsorship of the ASPET Datablitz presentations by young scientists at the upcoming ASPET Annual Meeting at Experimental Biology 2019 (EB19) in Orlando. PR&P will also launch a call for papers for an ECR themed issue ahead of the EB19 meeting. For this themed issue, the editors encourage ECR authors to consider submitting original research that confirms or disconfirms pharmacological hypotheses that were used as starting points for their doctoral research plus review manuscripts based on their doctoral thesis introductions. Such data sets are important and could help prevent unnecessary future experiments with the associated waste of time, money, animals and reagents.

Comments

Blog post currently doesn't have any comments.

If you are a British Pharmacological Society member, please sign in to post comments.

Back to Homepage

Published: 27 Mar 2019
Category: Journals, Early career pharmacologists
By Andrew Lawrence, Michael Jarvis

About the authors

Andrew Lawrence

Professor Andrew Lawrence is an NHMRC Principal Research Fellow & Associate Director at the Florey Institute of Neuroscience & Mental Health where he is Head of the Mental Health Research Theme. Andrew has published over 250 original articles & reviews, and been cited more than 9,300 times (H index 52). Andrew was Treasurer of the Australian Neuroscience Society (2002-08) and is a Fellow of the British Pharmacological Society. He was Senior Editor of The British Journal of Pharmacology (2007-14) and is currently a reviews editor with The British Journal of Pharmacology. He is Editor-in-Chief of Pharmacology Research & Perspectives.

Mike Jarvis

Mike has extensive experience in all phases of drug discovery research from target identification through clinical candidate selection and clinical development including proof of concept studies and life-cycle management. Currently, he provides scientific and medical oversight for established drug therapies in multiple therapeutic areas including epilepsy, pain, dyslipidemia, hypertension and metabolic disorders. Mike has served on numerous committees and editorial boards for the American Society for Pharmacology and Experimental Therapeutics (ASPET). He currently serves on the ASPET Board of Publication Trustees and is the Deputy Editor of Pharmacology Research & Perspectives.

Post archive